Overexpression of hypoxia-inducible factor-1α and vascular endothelial growth factor in sacral giant cell tumors and the correlation with tumor microvessel density.

Key Role of ROS in the Process of 15-Lipoxygenase/15-Hydroxyeicosatetraenoiccid-Induced Pulmonary Vascular Remodeling in Hypoxia Pulmonary Hypertension. PLoS One (2016) 0.80

Melatonin downregulates nuclear receptor RZR/RORγ expression causing growth-inhibitory and anti-angiogenesis activity in human gastric cancer cells in vitro and in vivo. Oncol Lett (2016) 0.75

Angiogenesis in cancer and other diseases. Nature (2000) 28.28

Targeting HIF-1 for cancer therapy. Nat Rev Cancer (2003) 28.01

Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A (1995) 24.77

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell (1996) 23.99

The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature (2008) 18.20

Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell (2008) 13.49

Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res (1999) 10.65

Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature (2006) 8.16

Giant-cell tumor of bone. J Bone Joint Surg Am (1987) 7.92

Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood (1996) 5.31

Giant cell tumor of bone. Orthop Clin North Am (2006) 3.07

Matrix metalloproteinase 9 and vascular endothelial growth factor are essential for osteoclast recruitment into developing long bones. J Cell Biol (2000) 2.87

Giant-cell tumor of bone. J Bone Joint Surg Am (1986) 2.78

Hypoxia-responsive transcription factors. Pflugers Arch (2005) 2.64

Relationship of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression to vascular endothelial growth factor induction and hypoxia survival in human breast cancer cell lines. Cancer Res (2000) 1.60

Hypoxia responsive gene expression is mediated by various subsets of transcription factors and miRNAs that are determined by the actual oxygen availability. New Phytol (2010) 1.32

An immunohistological study of giant-cell tumour of bone: evidence for an osteoclast origin of the giant cells. J Pathol (1985) 1.31

Harnessing the hypoxia-inducible factor in cancer and ischemic disease. Biochem Pharmacol (2006) 1.31

Gene expression in giant-cell tumors. J Lab Clin Med (2004) 1.26

Molecular profiling of giant cell tumor of bone and the osteoclastic localization of ligand for receptor activator of nuclear factor kappaB. Am J Pathol (2005) 1.26

Giant-cell tumor of bone with pulmonary metastases. J Bone Joint Surg Am (1985) 1.23

Patterns and variability of tumor oxygenation in human soft tissue sarcomas, cervical carcinomas, and lymph node metastases. Int J Radiat Oncol Biol Phys (1995) 1.21

Vascular endothelial growth factor receptors in osteoclast differentiation and function. Biochem Biophys Res Commun (2005) 1.21

Expression of VEGF and MMP-9 in giant cell tumor of bone and other osteolytic lesions. Life Sci (2003) 1.18

Hypoxia-inducible factor is expressed in giant cell tumour of bone and mediates paracrine effects of hypoxia on monocyte-osteoclast differentiation via induction of VEGF. J Pathol (2008) 1.17

Expression of osteoclast differentiation signals by stromal elements of giant cell tumors. J Bone Miner Res (2000) 1.16

Outcome of conservative surgery for giant cell tumor of the sacrum. Spine (Phila Pa 1976) (2009) 1.11

Giant cell tumor of the sacrum. Clin Orthop Relat Res (1993) 1.08

The farnesyltransferase inhibitor L744,832 reduces hypoxia in tumors expressing activated H-ras. Cancer Res (2001) 1.04

Malignant giant-cell tumours of bone. Clinico-pathological types and prognosis: a review of 29 cases. Int Orthop (1998) 1.03

Identification of markers of possible prognostic value in 57 giant cell tumors of bone. Oncol Rep (2003) 1.02

Surgical treatment of primary tumors of the sacrum. Clin Orthop Relat Res (1987) 0.97

Efficacy of radiotherapy for giant cell tumor of bone: given either postoperatively or as sole treatment. Int J Radiat Oncol Biol Phys (2001) 0.97

Axial shortening during distraction osteogenesis leads to enhanced bone formation in a rabbit model through the HIF-1alpha/vascular endothelial growth factor system. J Orthop Res (2006) 0.93

Concept, mechanisms and therapeutics of angiogenesis in cancer and other diseases. J Pharm Pharmacol (2003) 0.88

Microregional blood flow in murine and human tumours assessed using laser Doppler microprobes. Br J Cancer Suppl (1996) 0.87

Gene expression of vascular endothelial growth factor in giant cell tumors of bone. Hum Pathol (2000) 0.84

VEGF, FLT3 ligand, PlGF and HGF can substitute for M-CSF to induce human osteoclast formation: implications for giant cell tumour pathobiology. Lab Invest (2012) 0.82

Estrogen receptor expression in giant cell tumors of the bone. Hum Pathol (2002) 0.82

Expression of VEGF and its receptors and angiogenesis in bone and soft tissue tumors. Anticancer Res (2007) 0.82

Fine-needle aspiration cytologic diagnosis of giant-cell tumor of the sacrum presenting as a rectal mass: A case report. Diagn Cytopathol (2001) 0.78

Allicin inhibits oxidative stress-induced mitochondrial dysfunction and apoptosis by promoting PI3K/AKT and CREB/ERK signaling in osteoblast cells. Exp Ther Med (2016) 0.78